Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sarpogrelate HCl 300mg Tablets Under Fed Conditions
NCT03947528Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sarpogrelate in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area under the plasma concentration versus time curve. Status: unknown.
02
Drugs
sarpogrelate
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03947528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947528.